These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9643710)

  • 1. 150 years of pharmacovigilance.
    Routledge P
    Lancet; 1998 Apr; 351(9110):1200-1. PubMed ID: 9643710
    [No Abstract]   [Full Text] [Related]  

  • 2. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation.
    Daemmrich A
    Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740
    [No Abstract]   [Full Text] [Related]  

  • 3. The Federal Food and Drug Administration in the United States: born and bred in crises.
    Taylor WJ
    Int J Clin Pharmacol; 1973 Apr; 7(2):156-62. PubMed ID: 4581340
    [No Abstract]   [Full Text] [Related]  

  • 4. Two centuries of assessing drug risks.
    Avorn J
    N Engl J Med; 2012 Jul; 367(3):193-7. PubMed ID: 22808954
    [No Abstract]   [Full Text] [Related]  

  • 5. New drugs-miracles or mirages?
    JAMA; 2014 Jan 22-29; 311(4):423. PubMed ID: 24449329
    [No Abstract]   [Full Text] [Related]  

  • 6. The 1941 sulfathiazole disaster and the birth of good manufacturing practices.
    Swann JP
    Pharm Hist; 1999; 41(1):16-25. PubMed ID: 11623769
    [No Abstract]   [Full Text] [Related]  

  • 7. An historical overview over Pharmacovigilance.
    Fornasier G; Francescon S; Leone R; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):744-747. PubMed ID: 29948743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seeking medicine for the soul.
    Aronson SM
    R I Med J (2013); 2013 Jul; 96(7):11-2. PubMed ID: 23819133
    [No Abstract]   [Full Text] [Related]  

  • 9. The courage of one's convictions: the due diligence of Frances Oldham Kelsey at the FDA.
    Scheindlin S
    Mol Interv; 2011 Feb; 11(1):3-9. PubMed ID: 21441115
    [No Abstract]   [Full Text] [Related]  

  • 10. Show drugs work before selling them.
    Sipp D; McCabe C; Rasko JE
    Nature; 2017 Mar; 543(7644):174-175. PubMed ID: 28277530
    [No Abstract]   [Full Text] [Related]  

  • 11. Food and Drug Administration: 100 years of protection.
    Mosocco DJ
    Home Healthc Nurse; 2007 Mar; 25(3):148-50. PubMed ID: 17353704
    [No Abstract]   [Full Text] [Related]  

  • 12. [Status of side effects. 2. Adverse effects from a historical point of view. Classic examples].
    Lunde PK; Myhr K
    Tidsskr Nor Laegeforen; 1989 Nov; 109(31):3225-6. PubMed ID: 2688189
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA reorganization.
    Weissinger J
    J Parenter Sci Technol; 1988; 42(4):122-6. PubMed ID: 3054036
    [No Abstract]   [Full Text] [Related]  

  • 14. Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions.
    Motl S; Timpe E; Eichner S
    Am J Health Syst Pharm; 2004 Sep; 61(17):1840-2. PubMed ID: 15462254
    [No Abstract]   [Full Text] [Related]  

  • 15. The United States Food and Drug Administration and the practice of optometry.
    Lowther GE
    J Am Optom Assoc; 1979 May; 50(5):579-82. PubMed ID: 379116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration centennial: recognizing the guardians of our drug supply.
    Beary JF
    Arthritis Rheum; 2006 Oct; 54(10):3374. PubMed ID: 17009312
    [No Abstract]   [Full Text] [Related]  

  • 17. Bill Inman: drug safety physician and pharmacoepidemiologist.
    Shakir SA
    Drug Saf; 2006; 29(3):187-8. PubMed ID: 16524318
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA milestones.
    FDA Consum; 2006; 40(1):36-8. PubMed ID: 16528826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.